ANDA 74662, held by Boehringer Ingelheim. Ranitidine Hydrochloride.
As of Nov 15, 2026, ANDA 74662 (Ranitidine Hydrochloride), held by Boehringer Ingelheim, was first approved by FDA on Aug 29, 1997, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 29, 1997 | Original application | Approved | None posted |
| Ranitidine HydrochlorideEQ 150MG BASE · tablet;oral | Ranitidine Hydrochloride | Discontinued |
| Ranitidine HydrochlorideEQ 300MG BASE · tablet;oral | Ranitidine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
